ConductScience.org, home

Paper17516712

Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma.

Rao VP and 1 other. BioDrugs, 2007. Cited by 153 papers, by iCite.

Cite this record

ConductScience Library. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Papers, record 17516712. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17516712

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma.
PubMed
Journal
BioDrugs
PubMed
Year
2007
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
153
iCite
Relative citation ratio, by iCite
4.42
iCite
Revised in PubMed
2022-04-09
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rao VPVasantha P
2Epstein DLDavid L

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Enzyme InhibitorsMajor topic
GlaucomaMajor topic
Intracellular Signaling Peptides and ProteinsMajor topic
Protein Serine-Threonine KinasesMajor topic
rho GTP-Binding ProteinsMajor topic
Animals
Aqueous Humor
Axons
Eye
Ganglia
Humans
Muscle Contraction
Muscle, Smooth
Nerve Regeneration
Regional Blood Flow
Trabecular Meshwork
rho-Associated Kinases

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
EY013573NEI NIH HHSUnited StatesR01EY013573PubMed and NIHNIH RePORTER
EY12201NEI NIH HHSUnited StatesR01EY012201PubMed and NIHNIH RePORTER

Download CSV of grants

Cited by85

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 153 citations.

PMIDTitleJournalYearIn PapersSource
42603137Preparation of a new fixed-combination carteolol-netarsudil ophthalmic solution via one-pot pH-adjusting solubilization strategy for glaucoma treatment.Drug Deliv2026https://conductscience.org/library/papers/42603137PubMed
42317267Vascular regeneration and blood flow recovery in glaucoma.Front Cell Dev Biol2026https://conductscience.org/library/papers/42317267PubMed
42274198Effects of Ripasudil on Mouse Subconjunctival Immune Cell Motility Activated by Monocyte Chemoattractant Protein-1.Invest Ophthalmol Vis Sci2026https://conductscience.org/library/papers/42274198PubMed
41851243Isobaric quantitative proteomics reveals altered extracellular matrix, cytoskeletal, and degradation pathways in glaucomatous trabecular meshwork cells.Sci Rep2026https://conductscience.org/library/papers/41851243PubMed
40283958Rho Kinase (ROCK) Inhibitors in the Treatment of Glaucoma and Glaucoma Surgery: A Systematic Review of Early to Late Phase Clinical Trials.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40283958PubMed
39827971Optimized PLGA encapsulated SA-2 nanosuspension exhibits sustained intraocular pressure reduction in the mouse microbead occlusion model of ocular hypertension.Eur J Pharm Sci2025https://conductscience.org/library/papers/39827971PubMed
39818739Advancements and Prospects in Nanorobotic Applications for Ophthalmic Therapy.ACS Biomater Sci Eng2025https://conductscience.org/library/papers/39818739PubMed
39565302The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy.Invest Ophthalmol Vis Sci2024https://conductscience.org/library/papers/39565302PubMed
39115865Activation of the ROCK/MYLK Pathway Affects Complex Molecular and Morphological Changes of the Trabecular Meshwork Associated With Ocular Hypertension.Invest Ophthalmol Vis Sci2024https://conductscience.org/library/papers/39115865PubMed
39080269CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice.Nat Commun2024https://conductscience.org/library/papers/39080269PubMed
38983065Role of integrins in the development of fibrosis in the trabecular meshwork.Front Ophthalmol (Lausanne)2023https://conductscience.org/library/papers/38983065PubMed
38542203Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis.Int J Mol Sci2024https://conductscience.org/library/papers/38542203PubMed
38416395Rho Kinase Inhibitors: Strategies in Glaucoma Treatment in Older Adults.Drugs Aging2024https://conductscience.org/library/papers/38416395PubMed
38399328Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches.Pharmaceutics2024https://conductscience.org/library/papers/38399328PubMed
38242088A multi-cohort genome-wide association study in African ancestry individuals reveals risk loci for primary open-angle glaucoma.Cell2024https://conductscience.org/library/papers/38242088PubMed
38001960Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future.Biomedicines2023https://conductscience.org/library/papers/38001960PubMed
37873757Connective tissue growth factor: Role in trabecular meshwork remodeling and intraocular pressure lowering.Exp Biol Med (Maywood)2023https://conductscience.org/library/papers/37873757PubMed
37332549Efficacy of ripasudil in reducing intraocular pressure and medication score for ocular hypertension with inflammation and corticosteroid.Int J Ophthalmol2023https://conductscience.org/library/papers/37332549PubMed
36936709Exosomal miR‑152‑5p/ARHGAP6/ROCK axis regulates apoptosis and fibrosis in cardiomyocytes.Exp Ther Med2023https://conductscience.org/library/papers/36936709PubMed
36230968The Effects of Cannabidiol on Aqueous Humor Outflow and Trabecular Meshwork Cell Signaling.Cells2022https://conductscience.org/library/papers/36230968PubMed

See all 85 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ROCK16093PubTator's text mininghttps://conductscience.org/library/genes/6093NCBI Gene
ROCK29475PubTator's text mininghttps://conductscience.org/library/genes/9475NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17516712

GET https://conductscience.org/api/papers/v1/17516712/cited_by?page=2